Emerging company profile: The US biotech is wrapping up a Phase I trial for its lead pancreatic cancer program at the end of this year and hopes to expand its precision drug-device combination platform to a range of other solid tumors. PanTher Therapeutics’ Sagitarri™ platform brings a novel spin to traditional oncology drugs, helping deliver active ingredients to the tumor without affecting the bloodstream leveraging interventional oncology procedures.
PanTher Therapeutics Secures Patent for Anticancer Drug-Eluting Stent
PanTher announced that a methods-of-use patent for a deployable anticancer drug-eluting stent, exclusively licensed to PanTher, has been issued by the USPTO. The patent increases the potential applicability of PanTher’s proprietary Sagittari™ treatment platform, which focuses on direct, localized, and sustained delivery of proven and novel therapeutic agents to attack cancer at the source. PanTher also announced Dan Wildman as a strategic advisor. A seasoned executive with more than 35 years of experience in the MedTech industry, Mr. Wildman previously led the Digital Surgery Strategy initiative at Johnson & Johnson and served as worldwide president of DePuy Synthes Spine and Ethicon Biosurgery.
NEVY Awards Winner – “Emerging MedTech Company of the Year”
Last night the New England Venture Capital Association (NEVCA) honored the winners of its ninth annual NEVY Awards, recognizing and celebrating the top innovators, investors and companies in the region. The theme this year highlighted the “heroes” of New England’s innovation ecosystem — the entrepreneurs and investors committed to leveraging science and technology for a better tomorrow. We’re honored to receive the recognition for “Emerging MedTech Company of the Year” among Boston’s top startups and late-stage companies at the 9th annual NEVY Awards! 💥A big thank you to the New England Venture Capital Association and their Academy members for the recognition and a shoutout to our team 🦸🏻♀️🦹 that made this win possible.
PanTher Therapeutics Doses First Two Patients in Phase 1 Trial of PTM-101 for Treatment of Pancreatic Cancer
PanTher announced today the dosing of the first two patients in its Phase 1 clinical trial of PTM-101 for the treatment of pancreatic cancer. This first-in-human trial will evaluate feasibility, safety, and pharmacokinetics of PTM-101 when used as part of a standard procedure for treatment of patients with locally advanced pancreatic adenocarcinoma. “Launching the PTM-101 Phase 1 trial signals a major step toward our goal of improving therapeutic options for patients with difficult-to-treat solid tumors,” said Laura Indolfi, PhD, Chief Executive Officer of PanTher Therapeutics. “We are thrilled to partner with Dr. Charles Pilgrim and his team at The Alfred Hospital in Melbourne as we incorporate PTM-101 into the treatment for patients with locally advanced pancreatic cancer.”
Becoming A Clinical-Stage Biotech (Requires login)
Life Science Leader’s October 2019 issue featured Laura Indolfi, CEO and co-founder of PanTher Therapeutics, in an article titled “Program Winners Look Back On Year Of Change.” Her company, which makes minimally invasive implantable devices that deliver direct, localized, and sustained cancer therapy to solid tumors, won the first Massachusetts Next Generation Initiative (MassNext-Gen), a competitive program to support women entrepreneurs in early-stage life sciences companies. In June of 2021, PanTher closed an oversubscribed $5.4M Series A round, which set the stage for the company’s first clinical trial. Life Science Leader asked her to share some of her learnings from this key milestone and from the company’s decision to expand its board.
PanTher Therapeutics Receives Ethics Approval to Initiate Phase 1 Clinical Trial of PTM-101 in Australia
PanTher announced today that it received approval from the Human Research Ethics Committee (HREC) to open a Phase 1 clinical trial of PTM-101 in Australia. PTM-101 is being developed for the treatment of pancreatic cancer. The company also announced today the appointment of J. Marc Pipas, MD, as Chief Medical Officer and the establishment of its clinical advisory board. Dr. Pipas, a veteran GI oncologist and clinical trialist who has assisted in the development of multiple oncology agents from Phase 1 trials through commercialization (including ONIVYDE®, which received approval from the FDA for pancreatic cancer and was subsequently sold to Ipsen Pharmaceuticals for $1 billion), will direct PanTher’s clinical development programs.